JG
PTCT icon

Jefferies Group’s PTC Therapeutics PTCT Stock Holding History

Jefferies Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-54,000
Closed -$2.59M – 2542
2019
Q4 		$2.59M Buy
+54,000
New +$2.29M 0.02% 895
2018
Q2 		– Sell
-5,000
Closed -$135K – 2604
2018
Q1 		$135K Sell
5,000
-7,500
-60% -$190K ﹤0.01% 2026
2017
Q4 		$209K Buy
+12,500
New +$212K ﹤0.01% 2200
2017
Q1 		– Sell
-17,400
Closed -$190K – 2592
2016
Q4 		$190K Buy
+17,400
New +$183K ﹤0.01% 1925
2016
Q1 		– Sell
-13,100
Closed -$424K – 2497
2015
Q4 		$424K Sell
13,100
-127,100
-91% -$3.74M ﹤0.01% 1618
2015
Q3 		$3.74M Buy
140,200
+97,400
+228% +$4.17M 0.02% 620
2015
Q2 		$2.06M Buy
42,800
+30,000
+234% +$1.75M 0.01% 898
2015
Q1 		$779K Sell
12,800
-12,200
-49% -$744K ﹤0.01% 1171
2014
Q4 		$1.29M Buy
+25,000
New +$1.1M 0.01% 873

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jefferies Group's PTCT Position: Q4 2021 in Review

Jefferies Group sold out of PTC Therapeutics (PTCT) in Q4 2021, closing a stake of 12,600 shares — an estimated $469K sold.

Jefferies Group first reported a position in PTCT in Q1 2015 and held it in 11 quarters. The position peaked at $4.32M in Q4 2019. 178 funds tracked by Wall St. Rank hold PTCT as of Q4 2021.

  • Jefferies Group reported no remaining PTC Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 12,600 PTC Therapeutics shares in Q4 2021, an estimated $469K.
  • Jefferies Group first reported a position in PTC Therapeutics in Q1 2015 and held it in 11 quarters.
  • Jefferies Group's PTC Therapeutics position peaked at $4.32M in Q4 2019.
  • 178 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.